{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:02:06Z","timestamp":1778713326911,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University of California Davis","award":["CIID-2020-2"],"award-info":[{"award-number":["CIID-2020-2"]}]},{"name":"Vitalant","award":["A22-2082"],"award-info":[{"award-number":["A22-2082"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI118590"],"award-info":[{"award-number":["R01-AI118590"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Definitive data demonstrating the utility of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To better understand the mechanism of action of CCP, we studied viral replication and disease progression in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u2013infected hamsters treated with CCP obtained from recovered COVID-19 patients that were also vaccinated with an mRNA vaccine, hereafter referred to as Vaxplas. Vaxplas transiently enhanced disease severity and lung pathology in hamsters treated near peak viral replication due to immune complex and activated complement deposition in pulmonary endothelium, and recruitment of M1 proinflammatory macrophages into the lung parenchyma. However, aside from one report, transient enhanced disease has not been reported in CCP recipient patients, and the transient enhanced disease in Vaxplas hamsters may have been due to mismatched species IgG-FcR interactions, infusion timing, or other experimental factors. Despite transient disease enhancement, Vaxplas dramatically reduced virus replication in lungs and improved infection outcome in SARS-CoV-2\u2013infected hamsters.<\/jats:p>","DOI":"10.1093\/infdis\/jiad568","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T08:22:33Z","timestamp":1705047753000},"page":"1702-1710","source":"Crossref","is-referenced-by-count":4,"title":["Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2\u2013Infected Hamsters"],"prefix":"10.1093","volume":"229","author":[{"given":"Timothy D","family":"Carroll","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis , Davis, California , USA"},{"name":"California National Primate Research Center, University of California Davis , Davis, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis , Davis, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Kate","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Viral and Rickettsial Diseases, California Department of Public Health , Richmond, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Di Germanio","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-min","family":"Ma","sequence":"additional","affiliation":[{"name":"California National Primate Research Center, University of California Davis , Davis, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-2767","authenticated-orcid":false,"given":"Mars","family":"Stone","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Ball","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis , Davis, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Fritts","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis , Davis, California , USA"},{"name":"California National Primate Research Center, University of California Davis , Davis, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Rustagi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine , Palo Alto, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Simmons","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Busch","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-1975","authenticated-orcid":false,"given":"Christopher J","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis , Davis, California , USA"},{"name":"California National Primate Research Center, University of California Davis , Davis, California , USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, University of California Davis , Sacramento, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"2024061323532430700_jiad568-B1","author":"World Health Organization"},{"key":"2024061323532430700_jiad568-B2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"2024061323532430700_jiad568-B3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3390\/diagnostics11091663","article-title":"Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews","volume":"11","author":"Franchini","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2024061323532430700_jiad568-B4","first-page":"354","article-title":"The three pillars of COVID-19 convalescent plasma therapy","volume":"11","author":"Franchini","year":"2021","journal-title":"Life (Basel)"},{"key":"2024061323532430700_jiad568-B5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/vox.13091","article-title":"COVID-19 convalescent plasma therapy: hit fast, hit hard!","volume":"116","author":"Focosi","year":"2021","journal-title":"Vox Sang"},{"key":"2024061323532430700_jiad568-B6","doi-asserted-by":"crossref","first-page":"e0020021","DOI":"10.1128\/cmr.00200-21","article-title":"COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes","volume":"35","author":"Focosi","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2024061323532430700_jiad568-B7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.annonc.2021.07.015","article-title":"Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies","volume":"32","author":"Pommeret","year":"2021","journal-title":"Ann Oncol"},{"key":"2024061323532430700_jiad568-B8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/v14020226","article-title":"Spike gene evolution and immune escape mutations in patients with mild or moderate forms of COVID-19 and treated with monoclonal antibodies therapies","volume":"14","author":"Jary","year":"2022","journal-title":"Viruses"},{"key":"2024061323532430700_jiad568-B9","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024061323532430700_jiad568-B10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"2024061323532430700_jiad568-B11","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1093\/cid\/ciab721","article-title":"Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)","volume":"75","author":"Ong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024061323532430700_jiad568-B12","doi-asserted-by":"crossref","first-page":"E1619","DOI":"10.1503\/cmaj.211248","article-title":"Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada","volume":"193","author":"Fisman","year":"2021","journal-title":"CMAJ"},{"key":"2024061323532430700_jiad568-B13","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/bloodadvances.2022007410","article-title":"Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern","volume":"6","author":"Li","year":"2022","journal-title":"Blood Adv"},{"key":"2024061323532430700_jiad568-B14","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/bjh.18540","article-title":"Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy","volume":"200","author":"Gachoud","year":"2023","journal-title":"Br J Haematol"},{"key":"2024061323532430700_jiad568-B15","doi-asserted-by":"crossref","first-page":"e2250647","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024061323532430700_jiad568-B16","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.09.22278329","article-title":"COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trial","author":"Lacombe","journal-title":"BMJ Medicine"},{"key":"2024061323532430700_jiad568-B17","doi-asserted-by":"crossref","first-page":"e15274","DOI":"10.1172\/JCI152740","article-title":"A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia","volume":"131","author":"Avendano-Sola","year":"2021","journal-title":"J Clin Invest"},{"key":"2024061323532430700_jiad568-B18","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"2024061323532430700_jiad568-B19","doi-asserted-by":"crossref","first-page":"e1009925","DOI":"10.1371\/journal.ppat.1009925","article-title":"Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation","volume":"18","author":"Van Rompay","year":"2022","journal-title":"PLoS Pathog"},{"key":"2024061323532430700_jiad568-B20","doi-asserted-by":"crossref","first-page":"e0139721","DOI":"10.1128\/Spectrum.01397-21","article-title":"SARS-CoV-2 infection of rhesus macaques treated early with human COVID-19 convalescent plasma","volume":"9","author":"Deere","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2024061323532430700_jiad568-B21","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/trf.16555","article-title":"SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: dependency on assay format and applicability to serosurveillance","volume":"61","author":"Di Germanio","year":"2021","journal-title":"Transfusion"},{"key":"2024061323532430700_jiad568-B22","doi-asserted-by":"crossref","first-page":"e1009914","DOI":"10.1371\/journal.ppat.1009914","article-title":"The B.1.427\/1.429 (Epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters","volume":"18","author":"Carroll","year":"2022","journal-title":"PLoS Pathog"},{"key":"2024061323532430700_jiad568-B23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/ciab537","article-title":"Use of US blood donors for national serosurveillance of severe acute respiratory syndrome coronavirus 2 antibodies: basis for an expanded national donor serosurveillance program","volume":"74","author":"Stone","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024061323532430700_jiad568-B24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ajpath.2023.02.013","article-title":"Severe acute respiratory syndrome coronavirus 2 vasculopathy in a Syrian golden hamster model","volume":"193","author":"Ball","year":"2023","journal-title":"Am J Pathol"},{"key":"2024061323532430700_jiad568-B25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1046\/j.1471-4159.2003.02213.x","article-title":"Microglia\/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity","volume":"88","author":"Ohsawa","year":"2004","journal-title":"J Neurochem"},{"key":"2024061323532430700_jiad568-B26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"2024061323532430700_jiad568-B27","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.4049\/jimmunol.1003844","article-title":"Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2+ inflammatory monocyte\/macrophage-derived CCL11","volume":"186","author":"Waddell","year":"2011","journal-title":"J Immunol"},{"key":"2024061323532430700_jiad568-B28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2024061323532430700_jiad568-B29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","article-title":"Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities","volume":"151","author":"Gonzalez-Quintela","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 1","key":"2024061323532430700_jiad568-B30","first-page":"S336","article-title":"Treating the endotheliopathy of SARS-CoV-2 infection with plasma: lessons learned from optimized trauma resuscitation with blood products","volume":"61","author":"Pati","year":"2021","journal-title":"Transfusion"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad568\/55547503\/jiad568.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/6\/1702\/58211787\/jiad568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/6\/1702\/58211787\/jiad568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T13:40:34Z","timestamp":1718372434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/6\/1702\/7517344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2024,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad568","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2024,1,12]]}}}